Similar articles

• Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.

  Woodle ES, Thistlethwaite JR, Haas M, Josephson MA, Newell KA, Bruce DS, Millis JM, Piper JB, Charette JI. Woodle ES, et al. Transplant Proc. 1996 Apr;28(2):998-9. Transplant Proc. 1996. PMID: 8623495 Clinical Trial. No abstract available.
• Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation.

  Kliem V, Radermacher J, Hiss M, Pethig M, Burg M, Brunkhorst R. Kliem V, et al. Transplant Proc. 1999 Nov;31(7A):37S-40S. doi: 10.1016/s0041-1345(99)00792-7. Transplant Proc. 1999. PMID: 10576041 No abstract available.
• Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.

  Morrissey PE, Gohh R, Shaffer D, Crosson A, Madras PN, Sahyoun AI, Monaco AP. Morrissey PE, et al. Transplantation. 1997 Mar 27;63(6):845-8. doi: 10.1097/00007890-199703270-00009. Transplantation. 1997. PMID: 9089224
• Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection.

  Boratyńska M, Banasik M, Patrzałek D, Klinger M. Boratyńska M, et al. Ann Transplant. 2006;11(2):51-6. Ann Transplant. 2006. PMID: 17494290 Review.
• Protocol biopsy and subclinical rejection in patients after kidney transplantation treated by tacrolimus (Prograf).

  Zadrazil J, Krejcí K, Al Jabry S, Horcicka V Jr, Tichý T, Hrabalová M, Bachleda P. Zadrazil J, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2003 Dec;147(2):193-6. doi: 10.5507/bp.2003.028. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2003. PMID: 15037903 Review.